HK1024864A1 - Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery - Google Patents

Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery

Info

Publication number
HK1024864A1
HK1024864A1 HK00102585.7A HK00102585A HK1024864A1 HK 1024864 A1 HK1024864 A1 HK 1024864A1 HK 00102585 A HK00102585 A HK 00102585A HK 1024864 A1 HK1024864 A1 HK 1024864A1
Authority
HK
Hong Kong
Prior art keywords
lipid
efficient
preparation
nucleic acid
acid complexes
Prior art date
Application number
HK00102585.7A
Other languages
English (en)
Inventor
Demetrios Papahadjopoulos
Deelung Hong
Weiwen Zheng
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1024864A1 publication Critical patent/HK1024864A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK00102585.7A 1996-11-12 2000-04-28 Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery HK1024864A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3057896P 1996-11-12 1996-11-12
PCT/US1997/020690 WO1998020857A1 (en) 1996-11-12 1997-11-10 Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery

Publications (1)

Publication Number Publication Date
HK1024864A1 true HK1024864A1 (en) 2000-10-27

Family

ID=21854872

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00102585.7A HK1024864A1 (en) 1996-11-12 2000-04-28 Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery

Country Status (10)

Country Link
US (4) US6071533A (ja)
EP (1) EP0956001B1 (ja)
JP (2) JP2001510457A (ja)
AU (1) AU729655B2 (ja)
CA (1) CA2271325A1 (ja)
DK (1) DK0956001T3 (ja)
ES (1) ES2392246T3 (ja)
HK (1) HK1024864A1 (ja)
PT (1) PT956001E (ja)
WO (1) WO1998020857A1 (ja)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
ES2392246T3 (es) * 1996-11-12 2012-12-07 The Regents Of The University Of California Preparación de formulaciones estables de complejos de lípido-ácido nucleico para el suministro eficaz in vivo
WO1998046273A2 (en) * 1997-04-17 1998-10-22 Paola Leone Delivery system for gene therapy to the brain
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
AU747597B2 (en) * 1998-07-20 2002-05-16 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
US9034329B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
JP4799736B2 (ja) 1999-02-22 2011-10-26 ジョージタウン・ユニバーシティ 全身性遺伝子送達のための抗体フラグメント標的化イムノリポソーム
CA2362485A1 (en) * 1999-03-02 2000-09-08 The Liposome Company, Inc. Encapsulation of bioactive complexes in liposomes
AU5161800A (en) * 1999-05-24 2000-12-12 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
EP1754488A1 (en) * 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US7189705B2 (en) * 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
BRPI0111220B8 (pt) 2000-06-02 2021-07-27 Univ Texas conjugados de fármacos com etilenodicisteína (ec)
US6846809B2 (en) * 2000-09-25 2005-01-25 Board Of Regents, The University Of Texas System PEI: DNA vector formulations for in vitro and in vivo gene delivery
US20020146829A1 (en) * 2000-11-29 2002-10-10 Aventis Pharmaceuticals Products Inc. Neutral and anionic colloidal particles for gene delivery
WO2002078608A2 (en) * 2001-04-02 2002-10-10 Georgetown University A simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome or polyplex for systemic administration of a therapeutic or diagnostic agent
EP1610751A4 (en) * 2001-04-26 2006-05-24 Univ Texas AGENTE / LIGAND CONJUGATED THERAPEUTIC COMPOSITIONS, METHODS OF SYNTHESIS AND USE THEREOF
US20030203865A1 (en) * 2001-04-30 2003-10-30 Pierrot Harvie Lipid-comprising drug delivery complexes and methods for their production
US20050261214A1 (en) * 2001-05-15 2005-11-24 Serge Braun Complexes for transferring substances of interest into a cell
FR2829136B1 (fr) * 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
US20030049203A1 (en) * 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
KR100466254B1 (ko) * 2002-02-25 2005-01-14 한국과학기술원 세포내 전달을 위한 올리고뉴클레오티드와 친수성 고분자로 구성되는 유전자 전달용 접합체, 고분자 전해질 복합 미셀 및 그의 제조방법
AU2003237864B2 (en) * 2002-05-15 2008-12-18 California Pacific Medical Center Delivery of nucleic acid-like compounds
US20040137064A1 (en) * 2003-01-15 2004-07-15 Lewis David L. Compositions and processes using siRNA, amphipathic compounds and polycations
EP1513538A4 (en) * 2002-06-14 2007-08-22 Mirus Bio Corp Novel methods for introducing polynucleotides into cells
EP2316493A3 (en) * 2002-11-07 2011-08-10 Board of Regents, The University of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
WO2004064750A2 (en) 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
US7678540B2 (en) * 2003-10-16 2010-03-16 University Of Massachusetts Template-directed assembly of receptor signaling complexes
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US20050261221A1 (en) * 2004-03-01 2005-11-24 Li Wang Compositions and methods for enhanced delivery of compounds via transfection complexes
CA2562499A1 (en) * 2004-04-09 2005-11-24 Biodelivery Sciences International, Inc. Nucleotide-cochleate compositions and methods of use
JP2008526213A (ja) * 2004-12-30 2008-07-24 トッド エム． ハウザー， 自己保護オリゴヌクレオチドを使用する、遺伝子発現を調節するための組成物および方法
WO2006080118A1 (ja) * 2005-01-28 2006-08-03 Kyowa Hakko Kogyo Co., Ltd. 標的遺伝子の発現を抑制する組成物
US20090175930A1 (en) * 2006-01-11 2009-07-09 Nobuhiro Yagi Composition Suppressing The Expression of Target Gene in Eyeball and Medicament For Treating of Disease in Eyeball
CA2681795A1 (en) * 2006-03-24 2007-10-04 Gencia Corporation Synthetic lipid rafts and methods of use
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
JP6105187B2 (ja) 2006-04-25 2017-03-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｃｎｓ障害の処置のための成長因子の投与
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
KR20140135267A (ko) * 2006-05-15 2014-11-25 조지타운 유니버시티 치료제 또는 진단제의 전신 투여를 위한 항체- 또는 항체 단편-표적화 면역리포좀 제제 및 그의 용도
EP2049679A4 (en) * 2006-06-28 2010-02-24 P A Technologies Llc METHODS AND SUBSTANCES FOR IN VITRO ANALYSIS AND / OR USE OF PROTEINS ASSOCIATED WITH MEMBRANES, PARTS THEREOF VARYING THEREFROM
US20080213349A1 (en) * 2006-09-11 2008-09-04 Deepak Ramesh Thakker Liposome Complexes Containing Pharmaceutical Agents and Methods
JP5407862B2 (ja) * 2006-10-04 2014-02-05 サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィーク（セーエヌエールエス） ｓｉＲＮＡおよび脂質性４，５−二置換２−デオキシストレプタミン環アミノグリコシド誘導体を含む組成物ならびにその用途
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2136832B1 (en) 2007-03-26 2015-09-02 General Regeneratives Limited Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
EP2175835B1 (en) * 2007-07-09 2016-04-20 Georgetown University Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery
CN102065901B (zh) * 2008-06-19 2013-03-06 日本新药株式会社 药物载体
KR101209265B1 (ko) * 2008-12-26 2012-12-06 주식회사 삼양바이오팜 음이온성 약물 함유 약제학적 조성물 및 그 제조방법
TWI540319B (zh) 2010-03-29 2016-07-01 中央研究院 以細胞質譜分析定量細胞所攝入之奈米/微米粒子
JP5760562B2 (ja) * 2011-03-22 2015-08-12 セイコーエプソン株式会社 読取装置および読取方法
PT2760463T (pt) 2011-09-20 2019-02-27 Univ North Carolina Chapel Hill Regulação de canais de sódio por proteínas plunc
US9238865B2 (en) 2012-02-06 2016-01-19 Asm Ip Holding B.V. Multiple vapor sources for vapor deposition
AU2017222450A1 (en) 2016-02-22 2018-09-27 The University Of North Carolina At Chapel Hill Peptide inhibitors of calcium channels
US11788190B2 (en) 2019-07-05 2023-10-17 Asm Ip Holding B.V. Liquid vaporizer
US20220280652A1 (en) * 2019-07-10 2022-09-08 University Of Washington Non-viral immuno-targeting
US11946136B2 (en) 2019-09-20 2024-04-02 Asm Ip Holding B.V. Semiconductor processing device
GB202004254D0 (en) 2020-03-24 2020-05-06 Puridify Ltd Characterization of gene therapy vectors
WO2023054243A1 (ja) * 2021-09-30 2023-04-06 日油株式会社 細胞指向性を有する脂質ナノ粒子

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1308025C (en) * 1986-11-28 1992-09-29 Paul A. Tremblay Phospholipid composition
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
CA2133323C (en) * 1992-04-03 2010-10-26 Francis C. Szoka, Jr. Self-assembling polynucleotide delivery system
FR2722506B1 (fr) * 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
WO1996014864A1 (en) * 1994-11-09 1996-05-23 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
JP4338106B2 (ja) * 1995-06-07 2009-10-07 ライフ テクノロジーズ コーポレーション ペプチド増強カチオン脂質トランスフェクション
US5851818A (en) 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
ES2392246T3 (es) * 1996-11-12 2012-12-07 The Regents Of The University Of California Preparación de formulaciones estables de complejos de lípido-ácido nucleico para el suministro eficaz in vivo

Also Published As

Publication number Publication date
EP0956001B1 (en) 2012-09-12
EP0956001A4 (en) 2006-03-22
WO1998020857A1 (en) 1998-05-22
CA2271325A1 (en) 1998-05-22
US7462603B2 (en) 2008-12-09
EP0956001A1 (en) 1999-11-17
US6943027B2 (en) 2005-09-13
AU729655B2 (en) 2001-02-08
US20020182249A1 (en) 2002-12-05
JP4551464B2 (ja) 2010-09-29
US6071533A (en) 2000-06-06
JP2001510457A (ja) 2001-07-31
DK0956001T3 (da) 2012-10-22
AU7177998A (en) 1998-06-03
PT956001E (pt) 2012-12-06
US20050170509A1 (en) 2005-08-04
JP2008239631A (ja) 2008-10-09
US6410049B1 (en) 2002-06-25
ES2392246T3 (es) 2012-12-07

Similar Documents

Publication Publication Date Title
HK1024864A1 (en) Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
IL133348A0 (en) Stable insulin formulations
AU6600598A (en) Preparation having increased in vivo tolerability
AU2543795A (en) Methods of in vivo gene delivery
HUP0000829A2 (en) Stable liquid interferon formulations
IL126518A0 (en) In sequence delivery of messages
IL118419A0 (en) Delivery vehicles comprising stable lipid/nucleic acid complexes
HUP0104424A3 (en) Improved formulation for topical non-invasive application in vivo
HUP0103707A3 (en) Formulation of stable oxalyplatinum solution
HUP0001261A3 (en) Method of imaging cell death in vivo
EP0793501A4 (en) IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS
AU3190799A (en) Carrier for (in vivo) delivery of a therapeutic agent
ZA979175B (en) Novel piperidineketocarboxylic acid derivatives their preparation and use
PL325821A1 (en) Liquid acid netralising preparation
IL126984A0 (en) Phosphonic acid-substituted benzazepinone-n-acetic acid derivatives processes for their preparation and medicaments comprising these compounds
EP1037610A4 (en) COMPOSITIONS BASED ON LIPOSOMES COMPRISING CAMPTOTHECIN
ZA973097B (en) Novel aspire-hydroxy acid derivatives their preparation and use
IL116480A0 (en) Acetic acid deriratives their preparation and pharmaceutical compositions containing them
IL133176A0 (en) Pharmaceutical compositions of peptides having low solubility in physiological medium
SI0884053T1 (en) Stable insulin formulations
ZA98607B (en) Pulsatile delivery of diltiazem-HC1
IL127691A0 (en) Useful formulations of acid addition salt drugs
CY2293B1 (en) Slow-release pharmaceutical formulations containing mizolastin
IL136917A0 (en) Stabilization of lipid:dna formulations during nebulization
EP0673914A3 (en) Preparation of alpha-keto acid esters.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161110